Loading
Loading
Body Protection Compound 157 · TB-500 · GHK-Cu repair stack
BPC-157 promotes angiogenesis, accelerates fibroblast and endothelial cell migration to injury sites, and modulates the nitric oxide pathway. TB-500 (Thymosin Beta-4) sequesters G-actin to facilitate cell migration and reduce inflammation. GHK-Cu activates tissue-remodelling pathways via TGF-β and stimulates collagen synthesis.
Overview
BPC-157, Thymosin Beta-4 (Tβ4), and GHK-Cu are endogenously derived peptides that have been independently investigated in preclinical research for their roles in tissue repair, angiogenesis, extracellular matrix remodeling, and inflammation-associated cellular signaling. These peptides differ substantially in molecular structure and biological origin: BPC-157 is a stable gastric-derived pentadecapeptide, Thymosin Beta-4 is a ubiquitously expressed actin-binding peptide, and GHK-Cu is a copper-chelating tripeptide involved in redox- and matrix-related pathways. Despite these differences, experimental findings suggest that all three converge on overlapping regulatory processes involved in injury response and tissue remodeling.
In vitro and animal studies have associated BPC-157 with endothelial protection, fibroblast activation, and cytoprotective signaling; Thymosin Beta-4 with cell migration, progenitor cell recruitment, angiogenic signaling, and reduced fibrotic activity; and GHK-Cu with copper-dependent enzymatic activity, extracellular matrix synthesis, antioxidant defense, and gene expression modulation. Collectively, these mechanisms span multiple phases of tissue repair, including early inflammatory control, vascular regeneration, matrix deposition, and structural remodeling.At present, proposed synergistic interactions among BPC-157, Thymosin Beta-4, and GHK-Cu are based on mechanistic complementarity inferred from separate experimental models. No controlled studies have directly examined their combined effects, and all available data remain strictly preclinical and non-clinical, with no human trials evaluating combined exposure.
Compliance
Sold strictly as a research chemical for non-human, in-vitro, and laboratory use
FDA approved compound
Listed as prohibited under WADA anti-doping regulations
Prescription availability in Australia and internationally
In Australia, bpc-157, thymosin beta-4, and ghk-cu peptide has no TGA approval for therapeutic use. It is sold by Capital Precision Labs strictly as a research chemical for non-human, in-vitro, and laboratory research use only.
Pharmacology
BPC-157 promotes angiogenesis, accelerates fibroblast and endothelial cell migration to injury sites, and modulates the nitric oxide pathway. TB-500 (Thymosin Beta-4) sequesters G-actin to facilitate cell migration and reduce inflammation. GHK-Cu activates tissue-remodelling pathways via TGF-β and stimulates collagen synthesis.
Support
References
For research use only. Capital Precision Labs products are not approved by the TGA for therapeutic use. By purchasing you confirm you are a licensed research entity or qualified professional.